Influenza: Clinical sciences

1,967views

Influenza: Clinical sciences

Block 2 PHEENT

Block 2 PHEENT

Lung volumes and capacities
Pressure-volume loops
Changes in pressure-volume loops
Obstructive lung diseases: Pathology review
Chronic bronchitis
Alpha-1 antitrypsin deficiency: Year of the Zebra 2024
Emphysema
Chronic obstructive pulmonary disease: Clinical sciences
Bronchiectasis
Cor pulmonale
Asthma: Clinical sciences
Asthma
Asthma: Information for patients and families (The Primary School)
Restrictive lung diseases
Restrictive lung diseases: Pathology review
Approach to interstitial lung disease (diffuse parenchymal lung disease): Clinical sciences
Compliance of lungs and chest wall
Idiopathic pulmonary fibrosis
Approach to pneumoconiosis: Clinical sciences
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Pulmonary corticosteroids and mast cell inhibitors
Bronchodilators: Leukotriene antagonists and methylxanthines
Sarcoidosis
Hypersensitivity pneumonitis
Acute respiratory distress syndrome
Acute respiratory distress syndrome: Clinical sciences
Pulmonary hypertension
Pulmonary arterial hypertension (NORD)
Pulmonary edema
Atelectasis: Clinical sciences
Pneumonia
Pneumonia: Pathology review
Community-acquired pneumonia: Clinical sciences
Aspiration pneumonia and pneumonitis: Clinical sciences
Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Tuberculosis (pulmonary): Clinical sciences
Oral candidiasis
Plaque-induced periodontal disease diagnoses
Gingivitis and periodontitis
Risk factors for periodontitis
Diagnosis of periodontitis
Upper respiratory tract infection
Upper respiratory tract infections: Clinical sciences
Cytomegalovirus
Epstein-Barr virus (Infectious mononucleosis)
Streptococcus pyogenes (Group A Strep)
Mumps virus
Otitis media
Sinusitis
Bacterial epiglottitis
Croup and epiglottitis: Clinical sciences
Bordetella pertussis (Whooping cough)
Bronchiolitis: Clinical sciences
Respiratory syncytial virus
Antihistamines for allergies
Streptococcus pneumoniae
Hospital-acquired and ventilator-associated pneumonia: Clinical sciences
Klebsiella pneumoniae
Mycoplasma pneumoniae
Legionella pneumophila (Legionnaires disease and Pontiac fever)
Coronaviruses
COVID-19: Clinical sciences
Hantavirus
Mycobacterium avium complex (NORD)
Pseudomonas aeruginosa
Aspergillus fumigatus
Histoplasmosis
Coccidioidomycosis and paracoccidioidomycosis
Pneumocystis jirovecii (Pneumocystis pneumonia)
Influenza virus
Influenza: Clinical sciences
The flu vaccine: Information for patients and families
Respiratory distress syndrome: Pathology review
Sepsis
Sepsis: Clinical sciences
Lung cancer
Lung cancer: Clinical sciences
Lung cancer and mesothelioma: Pathology review
Pancoast tumor
Mesothelioma
Nasopharyngeal carcinoma
Thyroglossal duct cyst
Cleft lip and palate
Pierre Robin sequence: Year of the Zebra
Gorlin syndrome: Year of the Zebra
Gorlin syndrome (Gorlin Syndrome Alliance)
Periapical lesions
Aphthous ulcers
Oral cancer
Glaucoma
Warthin tumor
Nasal, oral and pharyngeal diseases: Pathology review
Human herpesvirus 8 (Kaposi sarcoma)
Uveitis
Anatomy clinical correlates: Eye
Approach to a red eye: Clinical sciences
Eye conditions: Inflammation, infections and trauma: Pathology review
Age-related macular degeneration
Eye conditions: Retinal disorders: Pathology review
Retinoblastoma
Sialadenitis
Laryngomalacia
Conductive hearing loss
Anatomy clinical correlates: Ear
Tympanic membrane perforation
Muscarinic antagonists
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Carbonic anhydrase inhibitors
Thyroid cancer
Hordeolum (stye)
Keratitis
Onchocerca volvulus (River blindness)
Acanthamoeba
Otitis media and externa (pediatrics): Clinical sciences
Acoustic neuroma (schwannoma)
Labyrinthitis
Meniere disease
Vertigo
Otitis externa
Neurofibromatosis
Eustachian tube dysfunction
Acute group A streptococcal infections and sequelae (pediatrics): Clinical sciences
Pharyngitis, peritonsillar abscess, and retropharyngeal abscess (pediatrics): Clinical sciences
Cataract

Decision-Making Tree

Transcript

Watch video only

Influenza is a highly transmissible viral infection that can primarily affect the upper and lower respiratory tract. It spreads via aerosols and directly infects the respiratory epithelium, causing inflammation. If you suspect influenza, you should determine whether your patient has a high risk of complications, and perform viral testing to confirm the diagnosis and guide treatment decisions.

Now, if a patient presents with signs and symptoms of influenza, you should first perform an ABCDE assessment to determine if they are unstable or stable. If they’re unstable, begin acute management. First stabilize their airway, breathing, and circulation. Next, obtain IV access and put your patient on continuous vital sign monitoring including heart rate, blood pressure, and pulse oximetry. Provide supplemental oxygen if they’re hypoxic, to maintain oxygen saturation above 90%.

Now let's go back to the ABCDE assessment and discuss the approach to stable patients. First, perform a focused history and physical examination. Your patient may report a sudden onset of fever, chills, myalgia, malaise, and headache. Additionally, local inflammation can result in dry cough, sore throat, and rhinorrhea. Your patient might also report exposure to a possible influenza contact within the previous 1 to 4 days, especially if there’s high transmission of influenza in the community.

Physical exam may reveal nonpurulent conjunctivitis, diaphoresis, and pharyngeal erythema, as well as abnormal lung sounds, such as crackles, rhonchi or wheezing.

At this point you can suspect influenza, so your next step is to assess whether your patient presents with high-risk features. Individuals are considered to be at high risk if they have chronic medical conditions, like diabetes, obesity, or heart disease, or if they are immunocompromised, like those with HIV or an organ transplant. In addition, certain populations are at higher risk, such as patients who are pregnant or less than 2 weeks postpartum, and those over the age of 65. Finally, individuals with severe or progressive symptoms, as well as patients who are currently hospitalized or living in a chronic care facility are also at high risk for influenza complications.

Ok, now let’s first consider patients who have no high-risk features. Your next step is to start supportive care, including the use of antipyretics as needed, promoting rest, and adequate hydration. Then, determine if testing for influenza will change your clinical management. Viral testing isn’t necessary in all situations; in fact, factors that indicate there’s no need for testing include patients without high-risk features who have symptoms that are highly suggestive of influenza, as well as if community transmission is known to be high like during the “flu season”, or if they don’t have any high-risk household contacts.

For most patients, all factors are present and testing is not indicated, so you can make a clinical diagnosis of influenza and continue supportive care. In addition, if their symptom onset was within 48 hours, you can consider offering them a neuraminidase inhibitor, or NAI, like oral oseltamivir. Lastly, encourage precautions for infection control until they have been fever-free for at least 24 hours.

However, if any of these factors is not present, testing for influenza will indeed change your clinical management, so you should order a nucleic acid amplification test, or NAAT. If the NAAT result is negative for influenza, you should consider alternative diagnoses, such as respiratory syncytial virus or RSV, parainfluenza virus, and SARS-CoV-2 infection. On the other hand, if the NAAT is positive, you can confirm the diagnosis of influenza. In this case, in addition to continuing supportive care, if your patient’s symptom onset was within 48 hours, you can prescribe a neuraminidase inhibitor, or NAI, like oral oseltamivir. In addition, patients with confirmed influenza should implement precautions for infection control until they have been fever-free for at least 24 hours. This includes standard precautions like handwashing, as well as droplet precautions like isolation or wearing a face mask

Alright, so now that we’ve reviewed what to do with a patient with no high risk features, let’s go back and talk about those who have 1 or more high risk features. The first thing you should do is obtain a nasopharyngeal specimen and send it for NAAT or, if your patient is hospitalized, you might order a polymerase chain reaction test, or PCR test for short. Start your patient on supportive care and an empiric NAI immediately, so don’t wait for the lab results. You can give oral oseltamivir, inhaled zanamivir, or a single dose of IV peramivir and consider hospitalization for patients with severe signs and symptoms.

Sources

  1. "Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa" Clinical Infectious Diseases (2019)
  2. "Influenza" BMJ (2016)
  3. "Harrison's: Principles of Internal Medicine" McGraw-Hill Education (2018)
  4. "Information for Health Professionals" CDC (2023)
  5. "Influenza Vaccination Resources for Health Professionals" CDC (2023)